Marchac A, Bosc R, Benjoar M-D, Hivelin M, Lepage C, Lantieri L
Service de chirurgie plastique réparatrice et esthétique, hôpital Henri-Mondor, Créteil, France.
Ann Chir Plast Esthet. 2011 Aug;56(4):275-9. doi: 10.1016/j.anplas.2011.06.001. Epub 2011 Jul 22.
We postulate that the absence of a CPT code for DIEP (deep inferior epigastric perforator) free flap in breast reconstruction is in part responsible for the delayed adoption of this modern technique in France. In order to provide data to our regulating health agency, we determined the cost of this technique compared to a gold standard. We performed a cost-identification study, comparing costs of DIEP free flap versus latissimus dorsi pedicled flap with implant (LD+I) in secondary breast reconstruction following irradiation.
Over a 12-month period, direct medical and non-medical costs as well as indirect costs were recorded in both groups (DIEP and LD+I).
In an academic department funded by the national health system, total cost of a secondary breast reconstruction by DIEP free flap was 10,671 ± 3005€ (n=57) versus 8218 ± 2049€ (n=18) for the LD+I group (P<0.05). Mean OR occupation time was 390 ± 64minutes for DIEP versus 283 ± 44minutes for LD+I (P<0.05). Mean hospital stay was 6 ± 2 days for DIEP versus 5 ± 2 days for LD+I (P>0.05).
DIEP free flap technique offers a long lasting breast reconstruction at an reasonable expense compared to the LD+I (+22%). Furthermore, in an academic department, collaboration of two microsurgeons during DIEP flaps allows OR times to drop significantly and become competitive with LD+I.
我们推测,在法国,乳房重建中缺乏用于腹壁下深动脉穿支(DIEP)游离皮瓣的现行程序编码,部分导致了这项现代技术的采用延迟。为了向我们的健康监管机构提供数据,我们确定了与金标准相比这项技术的成本。我们进行了一项成本识别研究,比较了DIEP游离皮瓣与背阔肌带蒂皮瓣联合植入物(LD+I)在放疗后二期乳房重建中的成本。
在12个月的时间里,记录了两组(DIEP和LD+I)的直接医疗和非医疗成本以及间接成本。
在一个由国家卫生系统资助的学术部门,DIEP游离皮瓣二期乳房重建的总成本为10671±3005欧元(n=57),而LD+I组为8218±2049欧元(n=18)(P<0.05)。DIEP的平均手术占用时间为390±64分钟,而LD+I为283±44分钟(P<0.05)。DIEP的平均住院时间为6±2天,而LD+I为5±2天(P>0.05)。
与LD+I相比(增加22%),DIEP游离皮瓣技术以合理的费用提供了持久的乳房重建。此外,在一个学术部门,两名显微外科医生在DIEP皮瓣手术中的协作可使手术时间显著缩短,并与LD+I具有竞争力。